2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4867
    β Amyloid (1-42) (scrambled)
    β Amyloid (1-42) (scrambled) is a negative control of β-Amyloid (1-42), human (HY-P1363A).
    β Amyloid (1-42) (scrambled)
  • HY-B1794AR
    Thiethylperazine dimaleate (Standard)
    		Inhibitor
    Thiethylperazine (dimaleate) (Standard) is the analytical standard of Thiethylperazine (dimaleate). This product is intended for research and analytical applications. Thiethylperazine dimaleate, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine dimaleate is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine dimaleate has anti-emetic, antipsychotic and antimicrobial effects.
    Thiethylperazine dimaleate (Standard)
  • HY-100604AR
    (R)-JNJ-40418677 (Standard)
    		Control
    (R)-JNJ-40418677 (Standard) is the analytical standard of (R)-JNJ-40418677 (HY-100604A). This product is intended for research and analytical applications. (R)-JNJ-40418677 is the R-enantiomer of JNJ-40418677 (HY-100604).
    (R)-JNJ-40418677 (Standard)
  • HY-123228
    CHF5022
    		Inhibitor
    CHF5022 is an inhibitor of Aβ42 secretion (IC50=92 μM). CHF5022 retains a modest activity on Aβ40 at non-cytotoxic concentrations (−22.2±4.8% at 100 μM).
    CHF5022
  • HY-N0022R
    Isoacteoside (Standard)
    		Inhibitor
    Isoacteoside (Standard) is the analytical standard of Isoacteoside. This product is intended for research and analytical applications. Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside Standard regulates the AKT/PI3K/m-TOR/NF-κB signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside Standard exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities.
    Isoacteoside (Standard)
  • HY-117259S
    Valiltramiprosate-d6
    		Inhibitor
    Valiltramiprosate-d6 (ALZ-801-d6) is deuterium labeled Valiltramiprosate. ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease.
    Valiltramiprosate-d<sub>6</sub>
  • HY-N9861
    Kayaflavone
    		Inhibitor
    Kayaflavone is an amentoflavone type biflavonoid. Kayaflavone has an inhibitory activity against amyloid-β42 cytotoxicity in PC-12 cells with an EC50 value of 5.29 μΜ. Kayaflavone is promising for research of Alzheimer’s disease.
    Kayaflavone
  • HY-50682R
    Azeliragon (Standard)
    		Inhibitor
    Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
    Azeliragon (Standard)
  • HY-126194
    Tolcapone 3-β-D-glucuronide
    		Inhibitor
    Tolcapone 3-β-D-glucuronide (Ro 61-1448) is an O-methyl metabolite of Tolcapone (HY-17406) and is pharmacologically inactive. Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma.
    Tolcapone 3-β-D-glucuronide
  • HY-105066R
    Davunetide (Standard)
    		Inhibitor
    Davunetide (Standard) is the analytical standard of Davunetide (HY-105066). This product is intended for research and analytical applications. Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity.
    Davunetide (Standard)
  • HY-103442R
    CGP52411 (Standard)
    		Inhibitor
    CGP52411 (Standard) is the analytical standard of CGP52411 (HY-103442). This product is intended for research and analytical applications. CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease.
    CGP52411 (Standard)
  • HY-11054
    TH-237A
    		98.55%
    TH-237A(meso-GS 164) is a neuroprotective agent with good blood-brain barrier permeability.
    TH-237A
  • HY-100642R
    3-O-Methyltolcapone (Standard)
    		Inhibitor
    3-O-Methyltolcapone (Standard) (Ro 40-7591 (Standard)) is the analytical standard of 3-O-Methyltolcapone (HY-174062). 3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma.
    3-O-Methyltolcapone (Standard)
  • HY-P5945
    β-Amyloid (1-8, A2V)
    β-Amyloid (1-8, A2V) is amutantion of β-Amyloid (1-8) (HY-P5946).
    β-Amyloid (1-8, A2V)
  • HY-N0442R
    5-O-Methylvisammioside (Standard)
    		Inhibitor
    5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) (Standard) is the analytical standard of 5-O-Methylvisammioside. This product is intended for research and analytical applications. 5-O-Methylvisammioside is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.
    5-O-Methylvisammioside (Standard)
  • HY-P5946
    β-Amyloid (1-8)
    β-Amyloid (1-8) is aAβ Fragment.
    β-Amyloid (1-8)
  • HY-P4885
    Glp-amyloid-β (3-40) peptide (human)
    Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice.
    Glp-amyloid-β (3-40) peptide (human)
  • HY-103241R
    Ro 90-7501 (Standard)
    		Inhibitor
    Ro 90-7501 (Standard) is the analytical standard of Ro 90-7501 (HY-103241). This product is intended for research and analytical applications. Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces Aβ42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response. Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner. Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells.
    Ro 90-7501 (Standard)
  • HY-105252AR
    BF 227 (Standard)
    BF 227 (Standard) is the analytical standard of BF 227 (HY-105252A). This product is intended for research and analytical applications. BF 227 is a candidate for an amyloid imaging probe for PET, with a Ki of 4.3 nM for Aβ1-42 fibrils.
    BF 227 (Standard)
  • HY-B0104S3
    Glimepiride-d4-2
    		Inhibitor
    Glimepiride-d4-2 (GliAmperide-d4-2) is deuterium labeled Glimepiride. Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.
    Glimepiride-d<sub>4</sub>-2
Cat. No. Product Name / Synonyms Application Reactivity